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We investigated efficacy of nitric oxide (NO) against Leishmania donovani. NO is a mediator of host
response to infection, with direct parasiticidal activity in addition to its role in signalling to evoke innate
macrophage responses. However, it is short-lived and volatile, and is therefore difficult to introduce into
infected cells and maintain inracellular concentrations for meaningful periods of time. We incorporated
diethylenetriamine NO adduct (DETA/NO), a prodrug, into poly(lactide-co-glycolide) particles of
~200 nm, with or without amphotericin B (AMB). These particles sustained NO levels in mouse
macrophage culture supernatants, generating an area under curve (AUC0.08-24h) of 591.2 ± 95.1 mM  h.
Free DETA/NO resulted in NO peaking at 3 h and declining rapidly to yield an AUC of 462.5 ± 193.4.
Particles containing AMB and DETA/NO were able to kill ~98% of promastigotes and ~76% of amastigotes
in 12 h when tested in vitro. Promastigotes and amastigotes were killed less efficiently by particles
containing a single druge either DETA/NO (~42%, 35%) or AMB (~90%, 50%) alone, or by equivalent
concentrations of drugs in solution. In a pre-clinical efficacy study of power >0.95 in the hamster model,
DETA/NO particles were non-inferior to Fungizone® but not Ambisome®, resulting in significant (~73%)
reduction in spleen parasites in 7 days. Particles containing both DETA/NO and AMB were superior (~93%
reduction) to Ambisome®. We conclude that NO delivered to the cytosol of macrophages infected with
Leishmania possesses intrinsic activity and adds significantly to the efficacy of AMB.
© 2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Oral chemotherapy of leishmaniasis consists of administration
of antimonials, miltefosine and paromomycin for about three
weeks (Sundar and Chakravarty, 2013). As a standard anti-
leishmanial chemotherapy, AMB is currently administered in anDivision, CSIR-Central Drug
Lucknow 226031, India.
Technology (INST), Phase-10,
y Research, Baylor Research
Bioengineering, Indian Insti-
dia.
half of Australian Society for Parainpatient setting, requiring infusion over several hours because of
its potential for generating acute nephrotoxicity and haemolysis
(Brajtburg et al., 1985; Deray, 2002). AMB, an antifungal drug, pri-
marily acts on membrane ergosterol and kills the parasite by dis-
rupting the surface membrane (Matlashewski et al., 2011). Drug
resistance to antimonials is spreading, and inclusion of liposomal
amphotericin B (AMB) in the treatment is increasingly recom-
mended (Balasegaram et al., 2012). Even in liposomal form, AMB is
administered by slow intravenous infusion, because of its toxicity
(Gahart et al., 2016). This is an inpatient procedure, and represents
additional burden in the resource-poor settings where visceral
leishmaniasis is prevalent.
To our knowledge, there are no new drugs for visceral leish-
maniasis in the drug discovery and development pipeline, but
several reports are available on anti-leishmanial agents incorpo-
rated in particulate delivery systems for use against experimentalsitology. This is an open access article under the CC BY-NC-ND license (http://
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Lopes et al., 2012; Asthana et al., 2013, 2015). There is scope to
improve upon such delivery systems to further ameliorate adverse
drug effects, prevent emergence of drug resistance, adapt systems
to outpatient use, and reduce cost to patients (Jha, 2006). We
therefore asked whether anti-leishmanial therapy may be
augmented with a novel pharmacophore, employed in unrelated
diseases, but relevant to the objective of killing the parasite within
the macrophage. NO is one such molecule and its role in innate
immune responses of mammalian macrophages is well known
(Ascenzi et al., 2003; Klink and Sulowska, 2007; Brune, 2010; Mills,
2012; Bogdan, 2015). The differences in NO cytotoxicity across
evolutionarily distinct genera suggest that it can effectively kill
bacteria, fungi and protozoa at concentrations that can be tolerated
by mammalian cells (Dzik, 2014). Bactericidal activity of NO against
a number of human pathogens has been extensively reported, and
our group has demonstrated the activity of NO prodrugs against the
macrophage-borne pathogen Mycobacterium tuberculosis (Verma
et al., 2012, 2013).
NO donors, also termed diazeniumdiolates or NONOates, are
formed by the chemical reaction of NO with nucleophilic amines
(Keefer and Saavedra, 2002) and can release NO in a sustained
manner. NO donors are essentially prodrugs, since the active moi-
ety, NO, is a gaseous molecule with a biological half-life (t1/2) of not
more than 2 min (Liu et al., 1998). NO donors like DETA/NO, iso-
sorbide mononitrate, sodium nitroprusside (SNP), 3-
morpholinosydnonimine (SIN-1), S-nitrosoglutathione (GSNO)
and S-nitroso- N-acetyl penicillamine (SNAP) are familiar phar-
macological agents. DETA/NO has a significantly longer half-life (t1/
2) of 20 h at pH 7.4 and 37 C; and releases two moles of NO per
mole of parent compound without prior biotransformation
(Yamamoto and Bing, 2000; Keefer and Saavedra, 2002; Xu et al.,
2011). NO has efficacy against Leishmania and the effective use of
NO donors in patients of cutaneous Leishmaniasis through topical
application of creams containing SNAP has been demonstrated
(Lopez-Jaramillo et al., 1998). NO-releasing diazeniumdiolates have
also been formulated as particles for topical treatment of cutaneous
leishmaniasis (Moreno et al., 2014).
Particulate drug delivery systems are taken up by macrophages,
which also represent the ecological niche for amastigotes of
Lesishmania species that cause visceral leishmaniasis. While the
promastigote is killed relatively easily by drugs in blood circulation,
the intracellular amastigote survives in phagosomes of tissue-
resident macrophages. The phagosome membrane acts as an
additional barrier to the entry of parasiticidal drugs circulating in
the bloodstream. Phagosome-resident amastigotes also evade
innate host defense mechanisms (Sacks and Sher, 2002) and
interfere with development of defensive immunity. Cytokines such
as gamma-interferon activate macrophages to produce NO which
kills intracellular Leishmania (Gatto et al., 2015). Mice deficient in
inducible NO synthase (iNOS) are more susceptible to Leishmania
infection (Green et al., 1990). Several membrane molecules of
Leishmania inhibit macrophage iNOS as part of the parasite's sur-
vival strategy inside macrophages, and cells expressing high levels
of iNOS are resistant to Leishmania infection (Proudfoot et al., 1996).
We employed a prodrug-in-particle approach to target NO to the
macrophage cytosol through passive internalization. The objective
of the present work was to establish ‘proof of principle'in respect of
the efficacy of NO against visceral leishmaniasis. Our approach also
involves incorporating multiple drugs, AMB and DETA/NO in the
same particle (Mi et al., 2013).We expected that NO delivered to the
macrophage cytosol will have important outcomes, both in terms of
killing the parasite as well as stimulating the host to mount defense
responses. Our observations suggest that the prodrug-in-particle
approach may be of use in targeting NO to infected macrophages,where the molecule exhibits parasite killing in vitro and in vivo,
without undue toxicity to the host cell.2. Material and methods
2.1. Materials
Biodegradable poly(lactic-co-glycolic acid) (PLGA) of monomer
ratio 65:35 was purchased from Birmingham Polymers Inc., (Bir-
mingham, AL, USA). DETA/NO, Cell culture medium (RPMI-1640),
fetal bovine serum (FBS), supplements and antibiotics; Pluronic F-
68 (Poloxamer 188); methylthiazoletetrazolium (MTT) and dialysis
tubing (70 KDa) were purchased from SigmaeAldrich (St. Louis,
MO, USA). AMB was donated by Sun Pharma Advanced Research
Centre, Vadodara, India. Acetone and methanol were of spectro-
scopic grade and all other reagents and chemicals were of analytical
grade. The water used in all experiments was prepared in a three-
stage Millipore Milli-Q plus 185 purification system (Bedford, MA,
USA).2.2. Preparation of particles
Particles were prepared by a solvent displacement method
(Pandya et al., 2011; Verma et al., 2011). PLGA was dissolved in
acetone by stirring at 37 C for 10 min to obtain a 2.5% (w/v) so-
lution. Methanol containing 4 M sodium iodide was used to solu-
bilize AMB to obtain a 0.1% solution (Lopes et al., 2014). Acetone and
methanol were used in a ratio of 1.5:1. DETA/NO was added to a
final concentration of 0.1% and the pHwas adjusted to 8.5. The drug
solution was then added to the polymer solution. FITC was also
added to the methanol solution to prepare fluorescent particles.
Then, 25 mL of the organic solution were added dropwize into
40 mL of distilled water containing 40 mg poloxamer 188 under
homogenization (IKA® Ultra TURRAX® model T-25) at room tem-
perature. The preparation was then placed in a rotary evaporator at
55e58 C under vacuum to evaporate the organic phase and
concentrate the aqueous phase to 10 mL. The aqueous preparation
was centrifuged at 70,000 rpm for 30min and the pellet lyophilized
to obtain particles in the dry state.2.3. Characterization
Particle morphology was studied using a Scanning Electron
microscope (Quanta 200, FEI, Oregon, USA). Three batches were
analyzed for size distribution (mean diameter and polydispersity
index) and Zeta potential using a Zetasizer NanoZS (Malvern In-
struments, UK). AMB content and encapsulation efficiency were
determined by a validated HPLC method, while the estimation of
DETA/NO was done by UV photometry of the ultracentrifugation
supernatant.2.4. In vitro drug release
The release of AMB from the particles was determined using a
dialysis membrane method. Each sample of drug loaded particles
(2 mL) was filled in dialysis bags with a molecular mass cut-off of
70 kDa. The bags were suspended in 200 mL of 0.1 M phosphate
buffer (pH 7.4) containing 1% v/v Tween 80, at 37 C in a USP
dissolution apparatus type II (DISSO-2000, LabIndia, Mumbai, In-
dia) running at 50 rpm. At predetermined intervals, aliquots of
0.5 mLwerewithdrawn and the amount of drug released estimated
by HPLC (Verma et al., 2011).
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Uptake of particles was assessed in J774 A.1mousemacrophages
using flow cytometry (FACS Aria, BD Biosciences, Heidelberg, Ger-
many). Cells were maintained in DMEM supplemented with 10%
FBS and 1% antimycotic-antibiotic mixture at 37 C, 5% CO2, and 95%
relative humidity. One million cells were plated per well in six-well
plates, incubated overnight and washed with incomplete medium
to remove non-adherent and dead cells. Particles containing FITC
alone (blank particles), or FITC in addition to AMB, DETA/NO alone,
or both drugs in the same particle were added to the designated
wells at drug concentrations of 50 mg/mL or FITC concentration
0.1 mg/mL. After 3 h of incubation, the culture medium was aspi-
rated and wells rinsed three times with incomplete medium to
remove extracellular particles. Cell-associated fluorescence was
measured at an excitation wavelength of 490 nm and an emission
wavelength of 525 nm. Histograms of fluorescence intensity versus
counts were plotted.
2.6. NO production
J774 cells were cultured as above in 96-well plates at a density of
0.5  106 cells/well. Solutions of AMB and DETA/NO, or a suspen-
sion of particles in DMEMwithout FBS or supplements were added
to a final concentration of 50 mM of either drug in wells assigned.
After 2 h, thewells were washed three times and complete medium
was replaced. NO2
 accumulation in the supernatant of cultured
cells was used as an indicator of NO production by the culture.
Supernatants from duplicate wells were recovered sequentially at
5, 15, and 30min, followed by 1, 3, 6, 12 and 24 h. NO in supernatant
was analyzed using Griess' reagent (0.2% naphthylenediamine
dihydrochloride, and 2% sulphanilamide in 5% phosphoric acid)
against a sodium nitrite standard curve at 540 nm (Powerwave-XS,
Bio-Tek Instruments).
2.7. Hemolysis
Hemolysis induced by the particles in fresh citrated mouse
blood was determined (Wang et al., 2006). With permission from
the Institutional Animal Ethics Committee of CSIR-CDRI, (IAEC/
2008/25/Renew 06-65/13), blood was collected from the tail vein of
mice. Particles were incubated with citrated blood at 37 C for 2 h,
and then centrifuged at 3000 rpm for 5 min. The hemoglobin
released in the supernatant was measured spectrophotometrically
at 550 nm. The positive control comprized RBC suspension in 1%
Triton-X solution in PBS for surfactant lysis, and the negative con-
trol was RBC in PBS.
2.8. Cytotoxicity towards macrophages
The in-vitro cytotoxicity of formulations towards J774 cells was
measured by an MTT assay. Cells were seeded in 96 well plates at a
density of 0.2  106 and were allowed to adhere overnight. The
medium was replaced and cells incubated for different time in-
tervals (6, 48 and 72 h) with different formulations at equivalent
doses of particles. These doses generated a concentration of 50 mM
of AMB or DETA/NO in wells exposed to particles containing single
drugs and 25 mM in respect of particles containing both. Cells were
then washed twice and incubated in the presence of 5 mg/mL MTT
for 4 h at 37 C. DMSO (50 ml) was added to each well to solubilize
formazan crystals. The optical density was measured using a mul-
tiwell scanning spectrophotometer (Biotek Microplate Reader,
Dynatech Laboratories Inc., Chantilly, VA, US) at a wavelength of
550 nm.2.9. Parasites
The strain MHOM/IN/1980/DD8 (henceforth, DD8) strain were
grown and maintained at 25 C in M199 medium supplemented
10% FBS and 1% antimycotic-antibiotic mixture.2.10. In vitro activity against promastigotes
Promastigotes of late log phase were seeded at a concentration
of 5  105 cells/well in a 96-well flat-bottomed micro-titre plate
(Cellstar, NC, USA) and different concentrations of AMB and/or
DETA/NO (12.5, 25 and 50 mg/mL of either drug) were generated by
adding free drugs or particles. Untreated cells served as the nega-
tive control. Each assay was performed in triplicate. The cells were
incubated for 48 h at 25 C after treatment. The promastigotes were
counted using a haemocytometer under a light microscope at 48 h
and 72 h. The % inhibition of parasite growth of treated cultures
were compared to that of untreated control.2.11. In vitro activity against amastigotes
J774A.1 cells (105 cells/well) were taken in 16-well chamber
slides (Nunc, IL, USA) and infected with late log phase DD8 pro-
mastigotes at a multiplicity of infection of 10. Prior to infection, the
cells were washed with medium to remove the non-adherent
macrophages. After 12 h, the chamber slides were washed three
times with PBS (pH 7.2) to remove extracellular promastigotes and
complete medium replaced. Different concentrations of drugs
(12.5, 25 and 50 mg/mL) were added to the wells in triplicate and
incubated for 48 h. Cells were fixed in absolute methanol, stained
with Giemsa stain and examined under oil immersion objective
(Zeiss Axiovert 25). At least 100 macrophages were counted per
well. Untreated infected macrophages were used for comparing
numbers of infected cells and amastigotes per cell.2.12. In vivo evaluation in L. donovani-infected hamsters
All experiments were conducted under approval/supervision of
the Institutional Animal Ethics Committee of CSIR-CDRI (Reference
number IAEC/2008/25/Renew 06 (65/13)). The anti-leishmanial
activity of particles containing AMB, DETA/NO or both drugs was
determined using Fungizone® and Ambisome® as comparators, at
drug-equivalent doses of 1 mg/kg body weight. The Syrian golden
hamster model was employed (Gupta et al., 2007). Hamsters (n ¼ 3
per group) were infected with Leishmania donovani Dd8 promas-
tigotes and after 30 days of established infection, the animals were
injected 1 mg/kg equivalent doses of particles or comparators for 5
consecutive days by the intraperitoneal route. Infected untreated
hamsters served as positive controls. After 7 days of treatment, the
animals were sacrificed. Splenic dab smears obtained by necropsy
were microscopically examined using Giemsa-stained imprints
wherein the parasite burden was expressed in terms of Leishman-
Donovan units (LDU), according to the stauber's formula (Stauber
et al., 1958).
LDU or Stauber's count¼ (Number of amastigotes per 1000
nucleated cells  weight of organ in grams)  2  105
The percent parasite suppression (PS) was calculated using the
following formula.
PS ¼ 100 ½1 ðPT=PCÞ
where PT and PC denote the mean stauber's count of treated group
and control group respectively.
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All results are given as means ± SD. Differences between for-
mulations were compared using one-way analysis of variance
(ANOVA) on ranks. P < 0.05 denotes significance in all cases. All
comparisons of AMB and DETA/NO individually were at equal
concentrations, regardless of whether particles or free drug were
used. Amounts of AMB exposed to groups of animals or cells
receiving two-drug particles were lower than those receiving AMB
particles or free drug, since these doses were normalized for 50 mM-
equivalents of DETA/NO. For evaluation of efficacy, the power of the
study was first calculated using the primary outcome measure of
reduction in spleen parasite burden from 400 to 150 amastigotes/
100 macrophages after 7 days of stopping treatment. N ¼ 3 was
chosen to estimate differences by non-parametric analysis or by
one-way ANOVA on ranks at a power >0.95.
3. Results
3.1. Characterization of particles
The particle size and size distribution, zeta potential, AMB and/
or DETA/NO content, and encapsulation efficiency in respect of
different formulations is shown in Table 1. These results indicate
that the particles are adequate for preparing an intravenously
injectable formulation.
The particles appeared as spheres or deformed spheres in
scanning electron microscopy (Fig 1A) and displayed Gaussian size
distribution in suspension (Fig 1B). Particles released AMB in a
diffusion-controlled fashion (Fig 1C). An initial burst was followed
by sustained release. The in vitro drug release data were tested
against several kinetic models of drug release to elucidate the
mechanism, and it was concluded that diffusion controlled release
conforming to the Higuchi model supervened (Costa and Sousa
Lobo, 2001). A linear relationship was observed between the
amount of drug released and square root of time, with correlation
coefficients (R2) of 0.82 and 0.93 respectively for AMB and 2-drug
particles. These results suggest a role of DETA/NO as a release
modifier for AMB in 2-drug particles.
3.2. Macrophage uptake and elicitation of NO in culture
Particles containing traces of FITC alone (blank particles) were
taken up as avidly as those containing AMB within 2 h of exposure
to J774 mouse macrophages in culture, as shown in Fig 2A. More
than 90% of cultured cells took up particles containing the fluo-
rescent marker. Particles containing DETA/NO alone or in combi-
nation with AMB were indistinguishable in terms of uptake, but
differed from AMB or blank particles in extent of fluorescence
imparted to the cells. Brighter staining by blank and AMB particles
as compared to DETA/NO or two-drug particles is attributable to the
polydispersity of the different preparations.
Culture supernatants of J774 macrophages exposed to a solution
of DETA/NO, or to particles containing the prodrug for 2 h were
monitored for NO- levels for the next 12 h, as shown in Fig 2B. NO
generated by soluble DETA/NO peaked within 15 min and declined,Table 1
Mean particle size, polydispersity and Zeta potential of formulations with indicated entr
Particles Size (d50, nm) Polydispersity index Zeta potent
Blank 127.9 ± 3.6 0.07 ± 0.02 15.5 ± 7.4
AMB 171.8 ± 6.6 0.086 ± 0.05 6.75 ± 4.9
DETA/NO 178.7 ± 10.4 0.406 ± 0.01 14.8 ± 4.3
2-Drugs 201.4 ± 13.8 0.316 ± 0.00 16.6 ± 8.3while particle-incorporated DETA/NO resulted in NO levels peaking
later and lower. Differences in the areas under the concen-
trationetime curve (AUC) of NO elicited by soluble and particulate
DETA/NO were statistically in significant (one-way ANOVA on
ranks, P < 0.05), even when the dose of DETA/NO was reduced to
half in respect of particles containing both DETA/NO and AmB.
These results are depicted in Fig 2C.
3.3. Preliminary assessment of biocompatibility
None of the formulations induced significant haemolysis. Hae-
molysis following incubation with particles is depicted quantita-
tively in Fig. 3A. The particles induced negligible hemolysis at
50 mM-equivalent doses. Fig. 3B shows the cytotoxicity of different
formulations against uninfected J774 cells. Panel 3C shows results
obtained when cells were infected with L. donovani strain DD8 at
MOI of 10, 6 h prior to treatment. The control in Panel 3B represents
viability of uninfected cells receiving no treatment, and in Panel 3C,
infected cells receiving no treatment. In vitro evaluation of cyto-
toxicity was carried out over 72 h, and yielded intriguing data in
respect of DETA/NO. It appears that DETA/NO protected cells from
death over the first 6 h of exposure. AMB is a well-known cytotoxic
agent, and reduced cell viability to ~20% of untreated controls
within 6 h, regardless of whether it was administered as particles or
in solution.
3.4. In vitro activity against L. donovani
Anti-leishmanial activity against Dd8 promastigotes was
measured by counting method. The results were transformed to
display average % inhibition of parasite survival, and are shown in
Fig. 4. Dose-dependent inhibition of parasite growth was observed
with all particle formulations. Particles containing DETA/NO alone
showed little inhibitory activity at 12.5 mMand 25 mM, but at higher
concentrations, they led to a significant (P < 0.05) inhibition of
promastigotes. At 50 mM concentration, free DETA/NO effected
34.9% parasite inhibition, while particle-borne DETA/NO had no
significant difference in efficacy (41.71%). AMB in solution and AMB
particles showed 81.12 and 89.91 percent inhibition at 50 mM
respectively. Particles containing both AMB and DETA/NO inhibited
98.51% of free-living parasites at 50 mM.
Activity against L. donovani Dd8 amastigotes was evaluated by
staining and counting numbers of parasites/macrophage nucleus.
Blank particles were inactive against the resistant strain. DETA/NO
and AMB in solution at 50 mM resulted in per cent inhibition of
28.04 ± 8.18 and 61.54 ± 3.28 respectively with respect to infected,
untreated controls. Particles containing these two agents individ-
ually resulted in 51.13 ± 3.95 and 65.90 ± 5.97% inhibition respec-
tively, which was significantly greater than that observed with
blank particles (P < 0.00001). When both agents were incorporated
together in particles, inhibition was 76.41 ± 3.58%. Two-drug par-
ticles induced significantly higher inhibition as compared to par-
ticles containing either of the two drugs alone (P ¼ 0.00012, 0.046
in respect of DETA/NO and AMB). These results are summarized in
Fig. 4.
Blank or drug-free particles also inhibited promastigote survival,apment efficiency of process and drug loading; ± SD.
ial (mV) Entrapment efficiency (% w/w) Drug content (% w/w)
7 e e
4 61.04 ± 7.49 2.62 ± 0.37
6 48.05 ± 2.60 1.96 ± 0.62
6 76.4 ± 4.34 1.53 ± 0.37
Fig. 1. Particle characteristics. (A): Representative scanning electron micrograph of DETA/NO þ AmB particles. The scale bar represents 300 nm. (B): Volume-average size distri-
bution of (1): blank particles, (2): particles containing DETA/NO alone, (3): AMB alone, and (4): containing both agents. (C): Cumulative % AMB released in 72 h from AMB particles
(open symbols) and two-drug particles (filled symbols).
Fig. 2. Uptake of particles and production of NO by J774 cells in 30 min of exposure. (A): Fluorescence acquired by cells exposed to (1): no particles, (2): blank particles, (3): AMB
particles, (4): DETA/NO particles and (5): two-drug particles. (B): Nitrite in culture supernatant following exposure to 50 mM DETA/NO in solution (open squares) or particles (filled
squares). Particles containing both DETA/NO and AMB (filled circles) yielded a final theoretical concentrationof 25 mM DETA/NO, generating a profile of lower levels of NO secretion.
Particles containing AMB alone (open triangles), or no drug (open circles) did not evoke NO release that was significantly different from untreated cells (open diamonds). Means
(N ¼ 2) of the data are shown. (C): Areas under the NO concentrationetime curve (AUC0.08-24) derived by integration. The suffixes ‘s’ and ‘p’ to x-axis labels indicate ‘solution’ and
‘particles respectively while p2D corresponds to two-drug particles. Means (N ¼ 2) of the data are shown, significance at P < 0.05 compared to blank particles is denoted by an
asterisk (*).
Fig. 3. Preliminary assessment of biocompatibility and differential survival of infected versus infected cells (A): Hemolysis induced by particles at concentrations of 12.5- (open
bars), 25- (gray bars) and 50- (filled bars) mM-equivalent drug concentrations of particles. (B): Cell viability after exposure to 50 mM-equivalent drug concentrations of drugs in
solution or in particle form in the absence of intracellular L. donovani at 6 h (open bars), 48 h (gray bars) and 72 h (filled bars) post exposure. P2D and s2D correspond to particle
two-drugs and soluble two-drugs, respectively (C): Viability after cells were infected with L. donovani. The prefixes ‘p’ and ‘s’ refer to particulate and soluble material. Means
(n ¼ 3) ± SD are plotted.
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stress.3.5. In vivo activity in L. donovani infected hamsters
Ambisome® and Fungizone® were the comparators employed
here and the percent parasite suppression observed by their
administration was 88.30 ± 1.76% and 74.02 ± 5.38% respectively
Fig. 4. In vitro activity of AMB ± DETA/NO against Leishmania donovani. (A): Promastigotes and (B): Amastigotes of the laboratory strain Dd8. Soluble (s) or particle-borne (p) DETA/
NO displayed no significant (P > 0.05) differences in killing promastigotes and amastigotes at 50 mM equivalent concentration; while the presence of AMB imparted significant
differences in activity towards the two forms with promastigotes being more susceptible than amastigotes. Means (N ¼ 3) ± SD are plotted, and non-significant differences between
treatment groups in a single ANOVA are indicated as NS. Markers indicate significant difference at: (a) p < 0.0001 compared to blank particles, (b): p < 0.0001 between treatment
groups, (c): p < 0.001 between treatment groups, (d) p < 0.01 between treatment groups, and (e) p < 0.05 between treatment groups.
S. Pandya et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 125e132130(Table 2). Particles containing DETA/NO possessed significant
in vivo leishmanicidal efficacy (73.10 ± 2.50% suppression) that was
comparable to Fungizone®, but not Ambisome®. As expected, 2-
drug particles displayed the highest activity (92.82 ± 1.03% sup-
pression) among all formulations. DETA/NO particles effectively
reduced the splenic parasite burden at a dose of 1 mg/kg/day under
the treatment regimen employed. The significantly higher activity
of 2-drug particles is attributable to the combined anti-parasitic
effect of both AMB and NO prodrug. There was no significant dif-
ference observed in the leishmanicidal activities between particles
containing DETA/NO and Fungizone (P > 0.05). Significant differ-
ences (P < 0.05) were observed in activities of other particles and
the commercial formulation, having leishmanicidal activity in the
rank-order 2-drug particles > Ambisome®>AMB
particles > Fungizone®. The mean ranks of treatment groups
compared to the untreated control group (mean rank 2.0) in a
KruskaleWallis ANOVA were 2.0, 6.3, 6.7, 11.0, 14.0 and 17.00
respectively.Table 2
In vivo anti-leishmanial activity of particles containing AMB, DETA/NO, or both drugs, co
Treatment group (n ¼ 3) Untreated AMB D
LDU or Stauber's number (  108) 21.90 ± 1.79 3.55 ± 0.43*#y 5
Percent parasite suppression (%) e 83.72 ± 2.06*#y 73
The percent parasite suppression was calculated using the LDU/Stauber's count vs. unt
hamsters per group. The groups were compared using KruskaleWallis non-parametric a
*Significantly different when compared with untreated (P < 0.05), # Significantly diff
compared with Ambisome® (P < 0.05).4. Discussion
The use of AMB particles in PLGA has been proposed by several
researchers over the years (Van de Ven et al., 2012; Jain et al., 2014;
Ribeiro et al., 2014; Asthana et al., 2015; Gupta et al., 2015). A
particle formulation for targeted delivery of anti-leishmanial
agents to macrophages as reported earlier (Pandya et al., 2011),
has the potential to facilitate bolus, intravenous injection to out-
patients. However, in view of the relatively large dose volume to be
administered as a bolus, it would be advantageous if a drug com-
bination regimen could reduce the required dose of AMB
(Davidson, 1991). The present results suggest that the NO prodrug
DETA/NO possesses intrinsic leishmanicidal activity against pro-
mastigotes and amastigotes, especially if incorporated in particles,
comparable to the commercial formulation Fungizone®. It can be
used alone, or preferably, in combination with AMB for additive
effects on parasite inhibition if formulated as particles suitable for
intravenous injection.
Particles reported here were prepared by a scalable processmpared to Ambisome® and Fungizone®.
ETA/NO AMB þ DETA/NO Ambisome Fungizone
.89 ± 0.73*y 1.57 ± 0.23*#y 2.55 ± 0.36*# 5.62 ± 0.73*y
.10 ± 2.50*y 92.82 ± 1.03*#y 88.30 ± 1.76*# 74.02 ± 5.38*y
reated group as discussed in the experimental section. Data are Mean ± SD for 3
nalysis at 95% confidence intervals.
erent when compared with Fungizone® (P < 0.05), ySignificantly different when
S. Pandya et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 125e132 131(Section 2.2 and Table 1), not requiring the use of ultrasonic energy.
All particles in the preparation, however, were not spherical
although the preparations were fairly monodisperse (Fig. 1A,B).
Matrix-controlled release of AMB was observed from the particles,
suggesting that intracellular concentrations of released drug would
follow similar temporal profiles when the particles are taken up by
macrophages. We did not study the release of the prodrug (DETA/
NO) in these experiments, preferring instead to study the time ki-
netics of the active moiety (NO) in culture supernatants. As evident
from Fig. 2B, NO levels were sustained at 20e30 mM for a period of
24 h when mouse macrophages were exposed to particles con-
taining DETA/NO. These concentrations are similar to values re-
ported in respect of macrophages recovered from mice receiving
protective immunization against Leishmania infantum (Khoshgoo
et al., 2008).
Preliminary indicators of biocompatibility of the particles
(Fig. 3) are encouraging. It is premature to speculate whether cell
death induced by AMB and/or DETA/NO would provide benefit in
chemotherapy of leishmaniasis by virtue of denying intracellular
‘sanctuary’ to the parasite. Results shown in Fig. 4, however, sup-
port the view that host cell death could affect inhibition of parasite
growth. The findings are encouraging with regard to the safety of
proposed formulation, but more detailed investigations are
required for a tenable claim of safety.
It has been demonstrated elsewhere that lactide-glycolide par-
ticles show leishmanicidal activity (Costa Lima et al., 2014). There
was significant enhancement of activity of DETA/NO when incor-
porated in particles, towards amastigotes. While the differences in
the extent of parasite inhibition by soluble versus particle-borne
AMB are not statistically significant, it is expected that lower con-
centrationsmight reveal clearer differences in efficacy at equivalent
dose. Further, the lack of difference between activities of particulate
and soluble AMB suggests that the drug is capable of sufficient
intracellular accumulation in vitro, without the need for targeting.
We did not evaluate host responses of the macrophage in these
experiments. However, it is likely that uptake of particles may
induce macrophages to mount parasiticidal innate responses,
especially if the contents release NO, a known mediator of such
responses (Verma et al., 2012). Analogous results from our work on
macrophages infected with an unrelated pathogen, M. tuberculosis,
suggest that the presence of particles in the macrophage's intra-
cellular compartment induces a variety of processes indicative of
classical activation (Sharma et al., 2007). Both AMB and DETA/NO
can reportedly elicit the expression of iNOS in macrophages (Larabi
et al., 2001), presumably leading to enhanced intracellular NO. It is
also possible that NO might act directly on the parasite membrane.
We submit that these particles might be of interest to researchers
investigating host-pathogen dialectics in the context of Leishmania
where intracellular generation of NO could result in important
outcomes. The DETA/NO particles reported here can serve as a
biochemical tool to investigate effects of exogenous supplementa-
tion of what is essentially an innate host response.
We found compelling evidence of pre-clinical superiority of the
two-drug particles in comparison to marketed liposomal formula-
tions of AMB, and non-inferiority of particles containing DETA/NO
alone (Table 2). Thus, we submit that the prodrug-in-particle
approach to passively target NO to macrophages deserve further
investigation, especially to establish appropriate dosing regimens.
Finally, we submit that the only way to clinically deploy the
invaluable contributions of NO to stimulation of host macrophage
responses as well as parasiticidal chemotherapy of Leishmania
infection is through targeted delivery of NO donors to the macro-
phage cytosol.Conflicts of interest
None.
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